Makoto Ieguchi

Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles

Kensuke Ochi, Yataro Daigo, Toyomasa Katagiri et al. · International Journal of Oncology · 2004 · 100 citations

Medicine, Cancer Biology, Oncology +17

<scp>SYT</scp>‐<scp>SSX</scp> breakpoint peptide vaccines in patients with synovial sarcoma: <scp>A</scp> study from the <scp>J</scp>apanese <scp>M</scp>usculoskeletal <scp>O</scp>ncology <scp>G</scp>roup

Satoshi Kawaguchi, Tomohide Tsukahara, Kazunori Ida et al. · Cancer Science · 2012 · 95 citations · Full text

Pharmacy, Immunology, Pharmaceutical Biotechnology +17

Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma

Kazuhito Morioka, Chizu Tanikawa, Kensuke Ochi et al. · Cancer Science · 2009 · 94 citations · Full text

Medicine, Cancer Biology, Oncology +17

Prognostic implication of SYT-SSX fusion type in synovial sarcoma: A multi-institutional retrospective analysis in Japan

Satoshi Takenaka, Takafumi Ueda, Norifumi Naka et al. · Oncology Reports · 2008 · 60 citations · Full text

Medicine, Oncology, Pathology +13

Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan

Ikuo Kudawara, Yasuaki Aoki, Takafumi Ueda et al. · Journal of Chemotherapy · 2013 · 49 citations

Medicine, Oncology, Surgery +17